Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Splicing factor 3A subunit 3 (SF3A3) is a protein crucial for pre-mRNA splicing, functioning as the third subunit of the SF3A heterotrimeric complex within the U2 small nuclear ribonucleoprotein (snRNP) particle of the spliceosome. It is essential for the conversion of 15S U2 snRNP into the active 17S U2 snRNP, facilitating branch-point recognition and early spliceosome assembly. It contains a zinc finger domain required for interactions within the complex and binds RNA directly. SF3A3 has multiple transcript variants and is involved in additional cellular processes including RNA stabilization, degradation, and possibly direct chromatin interactions. Dysregulation of SF3A3 has been associated with cancer pathogenesis, especially as a modulator of metabolic pathways and cancer stem-like cell phenotypes in contexts such as MYC-driven breast cancer[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor 3A subunit 3 (SF3A3).